AG真人官方

Foundations Investment Advisors, LLC (FIA) has filed Amendment No. 5 to its Schedule 13G for the Hypatia Women CEO ETF (CUSIP 90214Q527), a series of the Two Roads Shared Trust. The filing, triggered as of 30 June 2025 and signed on 8 July 2025, discloses that FIA now reports zero shares beneficially owned, representing 0% of the outstanding class. FIA also reports no sole or shared voting or dispositive power over any shares.

Because beneficial ownership has fallen below the 5 % reporting threshold, FIA checks the box for 鈥淥wnership of 5 percent or less of a class鈥� and lists itself under Item 3(e) as an investment adviser registered under Rule 13d-1(b)(1)(ii)(E).

The absence of any remaining position suggests a complete exit or reclassification of shares previously held. No other entities are listed, and there is no indication of group activity, subsidiary involvement, or pending transactions. Certifications are routine and the document contains no financial statements or earnings data.

SeaStar Medical Holding Corporation (NASDAQ: ICU) filed an 8-K detailing three material developments that collectively strengthen short-term liquidity but introduce meaningful future dilution.

1. $6.15 million unit offering: On 20 June 2025 the company priced and, on 23 June, closed a best-efforts public offering of 4,935,385 common shares and 1,218,462 pre-funded warrants, each paired with one five-year Series A warrant and one 18-month Series B warrant. The units were sold at $0.65 (or $0.6499 for the pre-funded alternative). In total 12,307,694 new warrants were issued with a $0.65 strike price, while the pre-funded warrants carry a $0.0001 strike. H.C. Wainwright acted as placement agent, receiving a 7 % cash fee, a 1 % management fee, reimbursable expenses and 430,769 placement-agent warrants exercisable at $0.8125 until 2030.

Proceeds & use of funds: Net cash to SeaStar is estimated at $3.39 million after fees. Management believes existing cash plus the raise will fund operations into November 2025. The purchase agreement limits additional share issuances for 60 days and prohibits variable-rate financings for 12 months, reducing short-term overhang risk.

2. Cost-containment actions: Effective 17 June 2025, the board approved a 20 % reduction in CEO, CFO, CMO and director cash compensation, lowering monthly operating expenses by roughly $50,000. Together with earlier liability waivers that eliminated about $1.2 million in unpaid bonuses and fees, the company expects materially lower cash burn.

3. Nasdaq compliance update: Following a March 2025 hearing, SeaStar had until 22 June 2025 to restore stockholders鈥� equity above $2.5 million. Management asserts that the recent capital raise, liability extinguishment, expanding QUELIMMUNE revenues (six customers in Q2) and cost cuts place the company back in compliance with Listing Rule 5550(b).

Investment takeaways:

• The transaction alleviates immediate liquidity risk but extends the fully-diluted share count by up to 13 million shares (including placement-agent warrants).
• Cash runway remains relatively short (鈮� 5 months) and future capital will likely be required once warrant exercises or the $15 million Lincoln Park equity facility are tapped.
• Management compensation cuts signal shareholder alignment and aggressive expense discipline.
• Nasdaq listing status is tentatively secure, removing a key technical overhang.